Laihinen A, Rinne U K, Suchy I
Department of Neurology, University of Turku, Finland.
Acta Neurol Scand. 1992 Dec;86(6):593-5. doi: 10.1111/j.1600-0404.1992.tb05493.x.
Twenty patients with advanced idiopathic Parkinson's disease were studied, all having a deteriorating response to levodopa and suffering from daily fluctuations in disability. A double-blind randomized cross-over study was conducted. Basic levodopa and anticholinergic treatment was continued unchanged in all patients. The dose increment period of 4-8 weeks was followed by a 4 week treatment period on a fixed optimal dose. In both treatment groups the mean optimal daily dose of lisuride was 1.3 mg (range 0.2-2.4 mg) and that of bromocriptine about 15 mg (range 3.75-30.0), without any significant differences between the treatment groups. The addition of lisuride or bromocriptine to levodopa treatment resulted in a significant and equal further improvement of parkinsonian disability. The therapeutic profiles of both lisuride and bromocriptine were similar. There was significantly more improvement in tremor than in other parkinsonian symptoms. Both lisuride and bromocriptine elicited a significant improvement in fluctuations of disability. No significant differences between the treatments were observed. The occurrence of clinical side effects seemed to be similar with both treatment regimens. In advanced parkinsonian patients the therapeutic efficacy of lisuride seems to be equal to that of bromocriptine as far as parkinsonian disability and fluctuations in disability are concerned.
对20例晚期特发性帕金森病患者进行了研究，所有患者对左旋多巴的反应均逐渐恶化，且日常残疾程度存在波动。进行了一项双盲随机交叉研究。所有患者的基本左旋多巴和抗胆碱能治疗均维持不变。在4 - 8周的剂量递增期后，进入为期4周的固定最佳剂量治疗期。在两个治疗组中，利苏瑞ide的平均每日最佳剂量为1.3毫克（范围为0.2 - 2.4毫克），溴隐亭约为15毫克（范围为3.75 - 30.0毫克），治疗组之间无显著差异。在左旋多巴治疗中添加利苏瑞ide或溴隐亭均导致帕金森病残疾程度有显著且同等程度的进一步改善。利苏瑞ide和溴隐亭的治疗效果相似。震颤的改善明显多于其他帕金森病症状。利苏瑞ide和溴隐亭均使残疾程度波动有显著改善。未观察到两种治疗之间的显著差异。两种治疗方案的临床副作用发生率似乎相似。就帕金森病残疾程度和残疾程度波动而言，在晚期帕金森病患者中，利苏瑞ide的治疗效果似乎与溴隐亭相当。
